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The current treatment of Parkinson’s disease with dopamine-centric approaches
such as L-DOPA and dopamine agonists, although very successful, is in need of
alternative treatment strategies, both in terms of disease modification and symptom
management. Various non-dopaminergic treatment approaches did not result in a
clear clinical benefit, despite showing a clear effect in preclinical animal models. In
addition, polypharmacy is common, sometimes leading to unintended effects on non-
motor cognitive and psychiatric symptoms. To explore novel targets for symptomatic
treatment and possible synergistic pharmacodynamic effects between different drugs,
we developed a computer-based Quantitative Systems Pharmacology (QSP) platform
of the closed cortico-striatal-thalamic-cortical basal ganglia loop of the dorsal motor
circuit. This mechanism-based simulation platform is based on the known neuro-
anatomy and neurophysiology of the basal ganglia and explicitly incorporates domain
expertise in a formalized way. The calculated beta/gamma power ratio of the local field
potential in the subthalamic nucleus correlates well (R2 = 0.71) with clinically observed
extra-pyramidal symptoms triggered by antipsychotics during schizophrenia treatment
(43 drug-dose combinations). When incorporating Parkinsonian (PD) pathology and
reported compensatory changes, the computer model suggests a major increase in b/g
ratio (corresponding to bradykinesia and rigidity) from a dopamine depletion of 70%
onward. The correlation between the outcome of the QSP model and the reported
changes in UPDRS III Motor Part for 22 placebo-normalized drug-dose combinations
is R2 = 0.84. The model also correctly recapitulates the lack of clinical benefit for
perampanel, MK-0567 and flupirtine and offers a hypothesis for the translational
disconnect. Finally, using human PET imaging studies with placebo response, the
computer model predicts well the placebo response for chronic treatment, but not for
acute treatment in PD.
Keywords: Parkinson’s disease, systems pharmacology, drug treatment
Abbreviations: b/g, ratio of beta-power to gamma power; CB, cannabinoid system (receptor); CNS, central nervous systems;
COMT, catechol-O-methyl transferase; DA, dopamine; GPCR, G-protein coupled receptor; GPe, globus pallidus externa;
GPi, globus pallidus interna; L-DOPA = L-3,4-dihydroxyphenylalanine (precursor for dopamine); MAO-B, mono-amine
oxidase type B; MSN, medium spiny neuron, the dominant GABAerge cell type in striatum; NMDA, N-methyl-D-aspartate;
PDE-10A, phosphodiesterase 10A; PD, Parkinson’s disease; PET, Positron emission tomography; QSP, Quantitative Systems
Pharmacology; RE, reticular GABAergic thalamic interneuron; SN, substantia nigra; STN, subthalamic nucleus; STN b/g,
ratio of beta-power over gamma power of the local ﬁeld potentials in the subthalamic nucleus; TC, thalamocortical projection
neurons.
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INTRODUCTION
Drug development in CNS diseases is faced with a high rate of
failure in clinical trials and PD is no exception.
While animal models are very good at elucidating the
underlying molecular biology of individual targets and
their interaction with a number of pathways, they are less
predictive for clinical outcome of speciﬁc novel therapeutic
interventions.
Important translational issues that are beyond the reach
of animal models and aﬀect the outcome of clinical trials
include lack of attention to comedications, diﬀerences in aﬃnity
between identical targets in diﬀerent species, the formation
of unique human metabolites, human genotypes that interfere
directly or indirectly with the primary pharmacology, and the
appropriate patient population (for a review see, Geerts, 2009).
Interestingly, while the majority of clinical trial failures are
due to lack of eﬃcacy, often unexpected motor-related side-
eﬀects are observed in clinical trials for new antipsychotics such
as JNJ37822681, a highly selective low-aﬃnity dopamine D2
antagonist (Geerts et al., 2012) or the PDE-10A inhibitor (Zhang,
2010).
A number of novel in silico technologies as support for
drug discovery and development have been proposed (Butte
and Ito, 2012). Almost all of them are based upon statistical
data-mining and pattern recognition of large databases of drugs
and their clinical eﬀects and rely upon correlation rather than
causation.
Quantitative system pharmacology is a logical combination of
quantitative PharmacoDynamic modeling (Geerts et al., 2013b)
with the rich information derived from Systems Biology (Sorger
and Schoeberl, 2012). In the case of CNS diseases we can build
on the extensive expertise of computational neurosciences that
has been around for over 60 years since the seminal work of
Hodgkin and Huxley (Hodgkin and Huxley, 1952). In a recent
Big Science initiative, the Blue Brain project (Markram, 2012)
simulated the time-dependent membrane potential changes
and action potentials in a detailed computer model of a
human microcolumn, containing over 200 diﬀerent cell types
and a wide variety of voltage-gated ion channels. However,
although such a model can provide increased understanding of
the human neurobiology, it lacks aspects that could make it
useful for CNS drug discovery, such as application of human
pathology parameters from imaging and post-mortem studies;
neuropharmacological targets of CNS-active drugs, a proper
description of target engagement of these drugs and a calibration
using retrospective and historical clinical data.
We therefore developed, calibrated and validated a version
of a computational neurosciences model that includes these
quantitative pharmacological aspects in the framework of
neuronal circuits to make it more actionable for pharmaceutical
Research and Development. Such an approach falls under the
deﬁnition of QSP (van der Graaf and Benson, 2011; Sorger and
Schoeberl, 2012). The current platform covers clinical readouts in
schizophrenia (Geerts et al., 2012, 2013a, 2015; Spiros et al., 2012;
Liu et al., 2014), Parkinson’s (Spiros et al., 2013), and Alzheimer’s
disease (Roberts et al., 2012; Nicholas et al., 2013).
This report presents a computer-based disease-modeling
platform of the basal ganglia for assessing the motor-symptoms
observed in PD that is fully constrained by clinical data on rigidity
and dyskinesia.
While the original hypothesis of Parkinson’s pathology was
focused on activation imbalance in direct vs. indirect pathways
(Miller and DeLong, 1988), recent studies using information
obtained from electrodes implanted in basal ganglia regions
point to the encoding of information in local ﬁeld potential
oscillatory behavior in speciﬁc basal ganglia regions, notably the
STN (Alonso-Frech et al., 2006; Little et al., 2013). We therefore
deﬁne the readout of our computer model as the ratio of the
power contained in diﬀerent spectral bands of the STN, notably
in the beta over gamma band.
We start with calibrating the side-eﬀects liability of
antipsychotics in schizophrenia which covers a broad range
of receptor couplings in the model beyond the dopaminergic
system, because these drugs aﬀect many diﬀerent receptors.
Obviously in this case, we implement the appropriate
hyperdopaminergic state in the basal ganglia, derived from
imaging studies in human patients (Abi-Dargham et al.,
2000). By optimizing the correlation between the outcome of
historical trials and the model outcomes, the biological coupling
parameters in the computer model can be calibrated. With
this list of optimal coupling parameters, we can then proceed
to implementing Parkinsonian pathology (hypodopaminergic
state) and testing the eﬀect of therapeutic interventions.
Using this two-pronged approach ensures we capture a wide
dynamic range of the biological processes that drive motor
behavior.
In this way, such a QSP platform can become very useful
for CNS R&D in schizophrenia motor side-eﬀects, Parkinson’s
and Huntington’s diseases. By using such a humanized computer
model, we aim to increase the predictability of clinical outcomes
by running ‘virtual’ human patient trials allowing one to
determine the impact of comedications and genotypes on the
dose-response of a novel investigative drug. The input for
such a ‘virtual’ patient trial will be the complete pharmacology
against human targets of the drug under investigation and
the nature and dose of other comedications. The output of
the computer model is a dose-dependent in silico biomarker
(here the ratio of the power contained in beta and gamma
spectral bands of the STN local ﬁeld potential) that is calibrated
against the clinical UPDRS scale. We can then estimate an
anticipated clinical eﬀect size and optimize clinical trial design
for a new therapeutic intervention or estimate the impact
of comedications on the dose-response of a new therapeutic
intervention.
MATERIALS AND METHODS
Receptor Competition Model
Proper target engagement is a key issue in clinical development.
Often a therapeutic window is deﬁned as the ratio of the dose
for a side-eﬀect vs. the dose of a clinical eﬀect. Therefore, we
simulate target engagement of the drug at a speciﬁc dose using
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quantitative PET imaging displacement studies with speciﬁc
radiotracers, where available. In the case of antipsychotics, D2-
speciﬁc tracers, such as raclopride, IBZM, or fallypride are often
used. We developed a receptor competition synapse model that
simulates the competition between neurotransmitter, parent and
active metabolite and tracer for dopaminergic, serotonergic,
adrenergic, or cholinergic post-synaptic receptors (Spiros et al.,
2010). The synaptic model reﬂects the human dynamics of
the various neurotransmitters by calibrating the presynaptic
autoreceptor coupling physiology with fast cyclic voltammetry
data from rodents and primates and constrains it subsequently
by human imaging data. This allows one to derive free levels of
neurotransmitter and presynaptic ﬁring frequencies leading to
basal receptor activation levels in healthy subjects and patients.
Of importance for this paper, this leads to a substantial diﬀerence
between rodent and human dopaminergic dynamics (Spiros et al.,
2010).
Neural Microcircuit Model
Parameters of the neural microcircuit component include
channel kinetics, structure, conductances, and receptor eﬀects.
The channel kinetic parameters determine the time course and
voltage sensitivity of membrane and synaptic currents and
have been well-characterized by physiological experimentation
in vitro. Structural parameters deﬁne the dimensions of
compartments that represent neurons and are determined by
anatomical data and the minimal number of compartments
that are necessary to simulate the physiological activity of
the microcircuit. These parameters also deﬁne the connectivity
between neurons in the microcircuit and are constrained by
anatomical data. In addition, neuronal cells project to their
aﬀerent regions based on neuro-anatomical connectivity data.
The parameters for maximum conductances of membrane and
synaptic currents are adjusted for the initial tuning of each
neuronal circuit model to accurately simulate neural activity
at the system’s level, often measured in primates by single-
cell electrophysiology or local ﬁeld potentials from deep-brain
recording in patients or data from human EEG and fMRI. These
parameters are constrained by electrophysiological studies of
membrane current densities and synaptic currents, but are also
dependent on the speciﬁc implementation of the compartmental
models to represent biophysical microcircuits.
The change in receptor activation introduces pharmacology
in the models and allows one to calibrate the models with
human clinical data. The eﬀects of neural modulators such
as dopamine and serotonin are implemented by coupling the
activation of receptors to changes in membrane and synaptic
currents. These eﬀects tend to modulate, rather than drive, the
overall activity of the network. Reasonably small changes in
receptor activation will not cause drastic change to the overall
systems level behavior, but will produce measurable changes in
the model readouts. Therefore, we consider the modulation of
receptors by pharmacological agents to be a perturbation of the
state of the system, whether that state is normal or pathological.
We can thus use a ﬁrst-order (linear) approximation of the
changes caused by pharmacology to alter the eﬀects of receptor
activation.
Neuronal Models Using the NEURON
Simulation Package
Each cell type is modeled with membrane conductances to
simulate their functional role in the circuit, and for eﬀects
of receptor activations caused by the pharmacology to change
the spiking activity. Each compartment of each model neuron
obeys the membrane current balance equation of the Hodgkin-
Huxley formalism (Hodgkin and Huxley, 1952). The membrane
potential, V, is computed by numerically integrating the equation
for each compartment CdV/dt = ∑ ga(V−Ea)+Iex, where C
is the membrane capacitance, ga is the ionic conductance of a
speciﬁc type ion channel, and Ea is the reversal potential of that
ion channel. The sum is over all types of ion conductances in each
model compartment, and Iex represents an externally applied
current from synaptic currents.
Specific Model of Subcortical Circuitry to
Predict Effects of Drug Actions on
Clinical Scales
The model of a closed cortico-striatal-thalamo-cortical circuitry
consists of three components: striatum, STN-GP circuitry, and
thalamo-cortical circuitry (Figure 1) and is based on a previous
model (Pirini et al., 2009) where we have added all relevant
neuromodulator receptor eﬀects and subsequently implemented
PD pathology (see below). The STN-GP circuitry consists of two
segments of the GPe and GPi and the STN. The thalamus model
is extended from (Bazhenov et al., 1998) where speciﬁc receptor
eﬀects of interest for pharmaceutical research were added as part
of a thalamo-cortical model.
Striatum Component
The striatummodel simulates the processing capacity of MSNs in
the ventral striatum or nucleus accumbens (Spiros et al., 2012).
The model calculates the excitability of the MSN, the major
GABA-ergic cell type in the nucleus accumbens, when driven by
aﬀerent cortical projections. We simulate two types of MSNs: D1
cells that project to the direct pathway and D2 cells that project to
the indirect pathway.
In the D1+ cells of the direct pathway, D1 receptors mostly
aﬀect the Kir channel (Kuzhikandathil and Oxford, 2002), while
in D2+ cells (indirect pathway), D2 receptor activation mainly
aﬀects the A-type K+ current (Gabel and Nisenbaum, 1998; Falk
et al., 2006). In both MSN, D2 receptor activity modulates the
presynaptic Glu release on the aﬀerent cortical ﬁbers (Bamford
et al., 2004).
STN-GP Circuitry Component
The model for the direct and indirect pathways is based on the
(Rubin and Terman, 2004) model of STN, GPi, and GPe, and its
extension (Pirini et al., 2009). Each nucleus contains 16 neurons
with the following membrane currents: sodium current (Na+),
delayed rectiﬁer potassium current (Kdr+), T-type calcium
current (CaT++), L-type calcium current (CaL++) and a leak
current. Receptor modulation of these neurons by receptors of
the dopamine, serotonin, acetylcholine, and adrenergic systems
will be obtained from the literature.
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The STN, GPe, and GPi population is divided in two groups
of eight cells each. The D2-type MSN cells from the striatum
synaptically connects to the GPe neurons with a GABA current
and the D1-type MSN cells has a GABA synapse onto the GPi
neurons. Each GPe cell receives inhibitory input from three other
GPe cells in addition to excitatory input from three randomly
chosen STN cells. Each STN cell receives inhibitory input from
three GPe cells. Each GPi cell receives inhibitory input from one
GPe neuron and excitatory input from one STN neuron. All the
TC cells of the thalamus receive inhibitory input from eight GPi
cells. Synaptic couplings are implemented as shown in Figure 1.
Thalamo-Cortical Component
The thalamus model is based on the circuitry and cellular
properties (see below) with four thalamocortical neurons (TC)
that are excitatory, glutamatergic relay neurons that pass sensory
information to the cortex model described in (Bazhenov et al.,
1998). The four reticular neurons (Re) are inhibitory, GABAergic
feedback neurons that receive inputs from, and inhibit, TC
neurons. The synaptic interaction between these neuronal types,
and their intrinsic membrane properties, leads to oscillations and
suppression of multiple input signals.
The spiking property of TC neurons is caused by a fast
sodium channel, Na+ (for review, see Traub et al., 1991), a fast
potassium channel, K+ (Traub et al., 1991), a low-threshold
Ca++ channel, iTC (Huguenard and McCormick, 1992), a
hyperpolarization-activated cation channel, Ih (McCormick and
Huguenard, 1992; Destexhe et al., 1998), a potassium A channel,
Ka+ (Huguenard et al., 1991), and a potassium leak channel
(McCormick and Huguenard, 1992). For an Re cell, we included
a fast sodium channel, Na+, a fast potassium channel, K+, a
low-threshold Ca++ channel, iTC, and a potassium leak channel.
All parameters (channel kinetics, current densities, morphology,
and synaptic strengths) were set at the values given in Bazhenov
et al. (1998). Muscarinic M2 receptor activation increases the
maximum conductance of h channels in thalamocortical cells and
the maximum conductance of leak channels in reticular cells,
similar to the eﬀect of serotonergic 5-HT2A receptor activation.
The cortex contains pyramidal cells (Pyr) and inhibitory
basket cells (BCs) and is derived from the model described for
FIGURE 1 | The model framework for basal ganglion, cortex, and thalamus. Two types of medium spiny neurons in the striatum, D1 and D2, project inhibitory
(red) synapses to GPi (direct pathway) and GPe (indirect pathway) respectively. The GPe neurons are reciprocally coupled to themselves and the subthalamic nucleus
(STN). The STN projects excitatory (green) synapses to the GPi and the GPi projects inhibitory connections to the thalamus. Thalamocortical (TC) neurons excite
reticular (Re) neurons that reciprocally inhibit TC. Sensory input excites TC and TC projects to the cortex containing pyramidal cells (Pyr) and inhibitory basket cells
(BC). All cell types receive background excitatory and inhibitory fluctuating inputs that represent random synaptic activity. White rectangles represent membrane
currents and colored ovals represent receptor types coupled to the membrane and synaptic currents. See text for currents and receptor types. PD pathology (red
arrows) is implemented using DA neuronal cell death, mGluR2−3 dysfunction at the MSN-GPe (indirect pathway) connection and dorsal raphe changes; while
compensatory changes (green arrows) include changes in the GPe-STN coupling and DA synapse modification, such as D2R upregulation and DAT downregulation.
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working memory (Roberts et al., 2012; Geerts et al., 2013a).
Basically this version consists of 40 two-compartment pyramidal
cells and 20 two-compartment GABA inhibitory neurons. 60%
of the interneurons synapse on pyramidal cells, the remaining
part forming a microcircuit. The pyramidal cells are driven by
the thalamic projections and they project to the MSN neurons in
the striatum for both direct and indirect pathway and to the STN
for the hyperdirect pathway.
Synaptic Currents
The synaptic connections are based on the kinetics of AMPA,
NMDA, GABA-A, and mGluR currents. Excitatory synapses
include both AMPA (Destexhe, 1994; Jahn et al., 1998; Myme
et al., 2003) and NMDA (Jahr and Stevens, 1990; Destexhe, 1994;
Dalby and Mody, 2003) currents. Parameters include maximal
inward depolarizing conductance (g), rise time constant (trise),
and decay time constant (tdecay). Reversal potentials for these
excitatory conductances have been set to 0 mV (Traub et al.,
2004). The following equation describes the Na+ conductance
(gglu) of both AMPA and NMDA receptors used in this model
[Mg++block for NMDAR not shown (Jahr and Stevens, 1990)]:
gglu(t) = < g > (exp(−t/tdecay) – exp(−t/trise). We represent the
eﬀects of mGluR stimulation with a slow, depolarizing current
(Anwyl, 1999; Sidiropoulou et al., 2009). Inhibitory chemical
synapses represent GABA-A receptor currents (Destexhe, 1994;
Galarreta and Hestrin, 1997; Nusser et al., 1998; Destexhe et al.,
2001) using a similar scheme as excitatory synapses, with the
GABA-A (chloride) reversal potential and kinetics associated
with each cell type. Each model neuron receives ﬂuctuating
currents to simulate background synaptic bombardment by
excitatory and inhibitory neurons (Destexhe et al., 2001).
Power Spectrum Analysis
Synaptic currents are used to calculate frequency band activity
of local ﬁeld potentials. To extract the EEG signal from the
simulated network activity, we assume that synaptic currents in
pyramidal cells are the major contributing dipole that generates
ﬁeld potentials (Nunez and Srinivasan, 2006), because their large
number dominates the synaptic currents in other types of cells.
Evoked potentials are simulated by excitatory synaptic inputs
from a burst of spikes transmitted via AMPA andNMDA currents
to represent sensory inputs (Moxon et al., 2003a,b; Zachariou
et al., 2008). Gamma power (γ) is then calculated as the integral of
the gamma band (60–100 Hz), while beta-power (β) is calculated
as the integral over the explanded spectrum (12–50 Hz) for less
variability in a 2.5 s simulation than a more properly deﬁned
spectrum of 10–40 Hz.
Receptor Effects, Pharmacology, and
Disease State
Receptor Effects
The receptor eﬀects are coupled to membrane conductances and
synaptic currents. The receptor competition model (Spiros et al.,
2010, 2012) calculates the occupancy and activation percentage
of each receptor using the appropriate aﬃnities of the diﬀerent
drugs at their functional intrasynaptic concentration, which in
the case of antipsychotics, will be derived from human imaging
studies with the appropriate PET radiotracers. The percent
change in the maximum conductance will determine how the
membrane and synaptic currents change as a result of each drug-
dose combination. The modulation of voltage-gated ion channels
will lead to a change in spiking activity of the model and alter the
properties of oscillatory readouts.
Implementation of Receptor Pharmacology
Serotonin receptors modulate currents depending on location
and magnitude. Adrenergic receptor activation enhances K+
conductance at the soma of interneurons, decreasing GABA
neuron excitability and regulates transmission at glutamatergic,
but not at GABAergic synapses. Cholinergic eﬀects in pyramidal
cells are implemented by coupling the computed activation
of M1 receptors to potassium and leak conductances in the
model. Nicotinic receptors enhance GABA neurotransmission
and glutamate release in pyramidal and interneuron NMDA and
AMPA conductances. For a full list of the interactions with the
appropriate references see Supplementary Table S1.
Implementation of the Schizophrenia Pathology
Schizophrenia pathology is introduced in the model as changes in
the level of striatal dopamine, based upon human imaging studies
(Abi-Dargham et al., 2000) and other receptor densities changes
(Geerts et al., 2012; Spiros et al., 2012).
Implementation of Parkinson Pathology
We introduce PD pathology as a general decrease in dopamine
release for both direct and indirect pathways (reﬂecting SN
pathology of DA neurons). Reduced DA tone aﬀects considerably
the beta/gamma power ratio in the STN as measured from
deep-brain recordings in PD patients (Tan et al., 2013).
A compensatory upregulation of D2R and downregulation
of DAT has been observed in to post-mortem and imaging
studies (Piggott et al., 1999). Selective upregulation of D2R
was implemented with a function that adjusted the fraction of
high aﬃnity dopamine D2R from 75% (at normal dopamine
release) to 100% when DA release is limited to 5% of normal.
Downregulation of DAT was implemented using changes in the
half-life of synaptic DA from 50 ms (at normal dopamine release)
to 70 ms when DA release nears its theoretical limit of 0. The
selective loss of bidirectional plasticity at the MSN-GPe and GPe-
STN boundary (Thiele et al., 2014) was implemented by changing
the coupling factor at the boundary of these regions. Finally
changes in 5-HT tone on receptors in basal ganglia (Miguelez
et al., 2014) aﬀect the activation levels of all the diﬀerent 5-HTR.
Figure 1 gives an overview of the Parkinsonian pathological
changes and compensatory modiﬁcations.
Calibration of QSP Model with Clinical
Data
Motor Side Effects in Schizophrenia Patients during
Treatment with Antipsychotics
Using PubMed searches we generated a clinical database
of 76 tested drug-dose combinations derived from peer-
reviewed publications of double-blind therapeutic interventions
in schizophrenia that covers the period from 1988 to today
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(see Supplementary Table S2). The clinical data are for short-
term (4–12 weeks) studies on stable schizophrenia patients that
are switched to investigative antipsychotic treatment or placebo
after a 2 weeks washout. The database contains 27 diﬀerent
antipsychotics and cover over 30,000 patients, although we only
have access to group-average clinical readouts. None of the
studies test augmentation therapy with antipsychotics but most
of them (62%) compare a new drug with an existing active
comparator, the remainder of the studies includes a placebo arm.
We identiﬁed 327 clinical experimental conditions (including
placebo); for each drug-dose combination, a weighted average
is calculated using the actual number of patients in that study
resulting in 76 drug-dose combinations; 43 of which are report
on the fraction of patients needing anticholinergic medication
for treatment of their Parkinsonian Extra-Pyramidal motor-side
eﬀects used in this calibration.
Clinical Calibration of Parkinson’s Disease
Clinical data with regard to their eﬀect on the UPDRS scale are
available for 24 diﬀerent drugs including dopaminergic agents,
NMDA antagonists, AMPAkines, Adenosine A2A agonists,
MAO-B inhibitors, 5-HT2A antagonists, anticholinergics, SERT
inhibitors and COMT inhibitors leading to 34 drug-dose
combinations on the UPDRS Part III motor score with 12
corresponding placebo eﬀects (see also Supplementary Table S3).
Most patients are from Caucasian origin with a somewhat higher
fraction of men. We ended up with 163 individual drug-dose
combinations (including placebo) with 103 (63%) in combination
with optimal dose of L-DOPA, 17 (10%) in combination with
other Parkinson’s medication (but not L-DOPA), 35 (22%) stand-
alone and 8 (5%) cross-over studies. 59 conditions (36%) were
studied in early disease state (<5 years), 47 (29%) conditions in
moderate disease (5–10 years) and 57 (35%) in severe disease
(>10 years). Study duration ranged from acute (30 min) to
long-term (113 weeks), but for the calibration we restricted the
data-set to maximal duration of 12 weeks. Although the total
number of patients in this database is over 17,000, we have only
access to group-average values for clinical outcomes. Note that
all conditions did not report on the same clinical scale. UPDRS
Part III had 63 drug-dose combinations, the change in OFF time
had 41 drug-dose combinations, followed by UPDRS II (39),
change in UPDRS Total (29) and change in ON time (21).Wewill
simulate these detailed therapeutic interventions in the model
and compare the calculated model outcome (beta/gamma power
of local ﬁeld potentials in the STN) to actual changes in clinical
scales.
RESULTS
Calibration of the Network with
Parkinsonian Extra-Pyramidal
Side-Effect Profile of Antipsychotics
Antipsychotics do have a rich pharmacology and aﬀect many
receptors. Because the extra-pyramidal side-eﬀect is similar to
Parkinson’s symptoms of bradykinesia and rigidity, calibrating
the computer model with these clinical data will optimize the
seven coupling factors (see below) for a wide range of receptor
couplings. For each of the 43 antipsychotic-dose combinations we
ﬁrst calculate the striatal intrasynaptic functional concentration
of the antipsychotic parent molecule and its metabolite where
available from the observed D2R speciﬁc PET imaging tracer
displacement in schizophrenia patients (Spiros et al., 2012).
This ensures we use the actual functional brain concentration
for the active moiety. Using the appropriate aﬃnities of
the antipsychotic and its metabolites for all GPCR, we can
then calculate the changes in receptor activation levels for
all dopaminergic, serotonergic, adrenergic, and cholinergic
receptors in a schizophrenia pathology environment that are
aﬀected by that speciﬁc drug-dose antipsychotic treatment.
This leads to a change in the calculated beta/gamma
ratio of local ﬁeld potentials in the STN. Figure 2 shows
the correlation between model outcome and reported Extra-
Pyramidal Symptoms (EPS) liability. Adjusting seven parameters
(D1R eﬀect on D1+ MSN via Kir, D2R eﬀect on D2+ MSN
via K-A, D2R eﬀect on all MSN via AMPA and NMDA max
conductances, 5-HT2AR eﬀect on Py via HVA and Nap channels,
5-HT4R eﬀect on Pyr via Kdr and Kca channels, M1 mAChR
eﬀect on Pyr via Kdr channel, and D1R eﬀect on Pyr via AMPA
and NMDA max conductances from e-e connections) results
in a robust correlation between model outcomes and observed
clinical readouts. Lower calculated beta/gamma power ratios
correspond to lower liabilities of Parkinsonian motor side eﬀects
of speciﬁc drug-dose combinations.
Interestingly, the EPS liability of atypical antipsychotics that
have a substantial 5-HT2AR antagonism becomes attenuated
at higher doses, while the EPS liability of earlier-generation
typical antipsychotics such as Haldol continues to increase
monotonically. This is in line with clinical data on the eﬀect
of trazodone, suggesting that increasing 5-HT2A antagonisme
improves Parkinson’s symptoms (Werneck et al., 2009) and has
been demonstrated in an earlier version of the model before
(Spiros et al., 2013).
Implementation of Parkinson’s Pathology
In this section we introduce PD pathology in the QSP model.
Neuronal toxicity of dopaminergic neurons in the SN is
implemented using decreased DA release levels in the striatal
receptor competition model. In addition, we implement both an
upregulation of the high-aﬃnity D2R and a small compensatory
decrease of the DAT transporter, which leads to lower clearance
rates and a longer half-life for synaptic dopamine. These changes
are based on post-mortem studies in PD patients (Piggott et al.,
1999).
Figure 3A shows the eﬀect of decreased presynaptic DA on
striatal D1 and D2R activation levels; substantial declines in
receptor activation levels start to become prominent at dopamine
depletion levels well beyond 80%. Accordingly, the beta/gamma
ratio (Figure 3B) only starts to increase substantially for DA
depletion above 70%. This non-linear interaction between DA
levels, receptor activation and local ﬁeld potential oscillations
might explain some of the clinical observations that symptoms
arise only when a large majority of SN neurons have become
dysfunctional.
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FIGURE 2 | Correlation between calculated beta/gamma power ratio (STN b/g) for 43 schizophrenia drug-dose combinations in the QSP model and
reported extra-pyramidal Parkinsonian motor side-effect liability during a short-term clinical trial. The clinical readout is the fraction of patients switched
to anticholinergic medication at any time during the experimental drug treatment. Note that the correlation is quite substantial and much higher than the correlation
between side-effect liability and pure D2R antagonism, which is only 0.18 (Spiros et al., 2012).
FIGURE 3 | (A) Effect of decreased dopamine release (a measure for SN neurotoxicity) on activation of striatal D1 and D2 receptors. It is clear that substantial
decreases of receptor activation only arise at DA depletion levels of 80% and greater. (B) Impact of decreased dopamine release (a measure for SN neurotoxicity) on
the beta/gamma power ratio (STN b/g) of local field potential oscillations in the subthalamic nucleus. Interestingly the subthalamic nucleus beta/gamma ratio remains
relatively unchanged up to a depletion of 60% after which it increases monotonically.
We further tested the diﬀerential impact of neuroplasticity
at GPe-STN coupling compared to changes in MSN-Gpi
coupling on local ﬁeld potentials in STN under Parkinsonian
conditions. Supplementary Figure S1 shows that the GPe-STN
neuroplasticity changes impact beta/gamma readout much less
as compared to the MSN-GPe coupling changes. This illustrates
the complex relationship between biophysical processes and
emergent properties of the network, in this case the oscillations
of the local ﬁeld potential in the STN.
Clinical Results in Parkinson’s Disease
Treatment
L-DOPA vs. Partial D2 Agonists
This section deals with the impact of dopaminergic stimulations
on the beta/gamma readout. Dopaminergic stimulation can be
achieved with L-DOPA, a precursor for dopamine, MAO-B
inhibition of neurotransmitter degradation, and dopamine
agonists.
The ﬁrst two cases refer to an increased dopamine release from
presynaptic nerve terminals that activate both D1 and D2R in the
direct and indirect pathway.
The actual increase in dopamine release associated with a
speciﬁc dose of L-DOPA or an MAO-B inhibitor is unknown
as no good target engagement data are available. Microdialysis
studies in preclinical animal models (Sader-Mazbar et al., 2013)
suggest that MAO-B inhibition can easily more than double
the level of free ambient dopamine in vivo. On the other hand,
using RT-132 (a DAT tracer) PET imaging displacement in
early PD patients (Guttman et al., 2001), a 22% change was
observed after 3 weeks of treatment with 375 mg of L-DOPA
corresponding to a doubling of the presynaptic DA release
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calculated from our receptor competition model. However, in
advanced PD, L-DOPA maintenance dose can easily be in the
600–900 mg range. This suggests that MAO-B inhibition is
likely to achieve a somewhat smaller increase in free dopamine
as compared to L-DOPA with a corresponding smaller clinical
beneﬁt.
Many dopamine agonists have been tested in PD. We
studied the eﬀect of 12 diﬀerent compounds, including
pramexipole, rotigotine, ropinirole, the D1-agonist ABT431,
apomorphine and the somewhat older drugs like piribedil,
bromocriptine, terguride, cabergoline, lisuride, pergolide,
and quinpirole. They interact diﬀerently with the dopamine
receptors in terms of aﬃnity and maximal agonistic eﬀect.
In general, they tend to be more speciﬁc for the D2S
(assumed to be the presynaptic dopamine autoreceptor)
than for the D2L (post-synaptic dopamine receptor) and
have a low aﬃnity for the D1R, but interact strongly
with the hD3R. Notable exceptions are apomorphine
(acting on both D1 and D2R) and ABT431 (speciﬁc for
the D1R). Supplementary Figures S2 and S3 show the
pharmacology of the compounds on D1, D2S, D2R, and D3
receptors.
Figure 4A shows the eﬀect of diﬀerent DA agonists on the b/g
ratio. The diﬀerent aﬃnities for D1, D2S and D2L receptors result
in diﬀerent clinical outcomes.
Glutamatergic Interventions
A number of glutamatergic interventions have been tested
in the clinic, ranging from NMDA antagonism to NR2B
speciﬁc antagonism and AMPA modulation. The underlying
rationale for these targets is based on neuroprotection and
the preclinical observations of glutamate overload. Based
on studies from the Allen Brain Institute, it was found
that the NMDA-NR2B subunit was only present in cortical
areas.
After implementation of these biological processes, our
computer model predicts an increase in b/g ratio with increasing
NMDA antagonism (Figure 4B), suggesting a clear worsening
of clinical symptoms. For instance a 5% decrease in gNMDA
increases b/g between 3% when added to regular L-DOPA
dose to 9% as a stand-alone. Subsequent analysis of the
eﬀect of a speciﬁc NR2B antagonist resulted in a steeper
decline of gamma-band power than beta-band power with
decreasing conductance of this ligand-gated voltage channel,
resulting in an increased beta/gamma power ratio. This
suggests that glutamate antagonists in general tend to worsen
motor symptoms in the Parkinsonian disease state, in line
with observed clinical data on perampanel, MK-0567 and
amantadine.
An interesting drug is saﬁnamide, a combination of MAO-
B inhibition and NMDA antagonism. These opposing activities
tend to balance out; at lower doses the beneﬁcial MAO-B
inhibition eﬀect dominates, while at higher doses the negative
eﬀect of NMDA antagonism takes over. This is in line with
clinical observations (Stocchi et al., 2012) that both the 50 and
100 mg, but not the higher doses of 200 mg improved motor
symptoms.
Adenosine A2A Intervention
Diﬀerent inhibitors of the adenosine 2A (A2A) receptor pathway
have been tested in clinical trials. We implemented this eﬀect as a
speciﬁc co-regulation of the D2R in MSN neurons of the indirect
pathway. While A2A activation increases cAMP, corresponding
to lowering DA tone on the D2R (because of the Gi coupling),
blocking A2A decreases cAMP and ampliﬁes any eﬀect of D2R
stimulation, although there is no direct eﬀect on the output of
D1+ MSN neurons. We implemented the adenosine A2A eﬀect
as an increase in the coupling parameter between D2R activation
and changes in conductance of the A-type K+ channel. In line
with these ideas, we found that A2A antagonism works better
with increasing L-DOPA comedication (Figure 4C). The eﬀect,
however, is relatively modest.
Serotonin Modulation
Serotonin neurotransmission impacts basal ganglia network
dynamics through both direct and indirect ways. Post-synaptic 5-
HT4, 5-HT1B, and 5-HT1A receptors are located in pallidal brain
regions (Varnäs et al., 2003; Chen et al., 2008) and aﬀect excitation
and inhibition at STN glutamatergic neurons (Stanford et al.,
2005).
5-HT2A aﬀects the pyramidal cells in the motor cortex
and plays a role in suppressing tremor, one of the cardinal
phenotypes of PD. An earlier QSP model (Spiros et al.,
2013) illustrated the impact of 5-HT2A antagonists on the
cardinal feature of tremor; when implementing this eﬀect in
the current QSP model, 5-HT2A antagonism also decreases
beta/gamma ratio in a monotonic fashion. Also, lowering
5-HT tone in general tends to lower b/g ratio, suggesting
clinical improvement. This is in line with ﬂuoxetine reducing
depressive symptoms, but also its beneﬁcial eﬀect on motor
symptoms in a clinical open-label study (Kostic et al., 2012;
Figure 4D).
Clinical Calibration
The clinical database collected from publicly available data
(see Supplementary information) consists of 41 papers on 24
diﬀerent drugs. When considering changes in UPDRS Motor
Score Part III, we can extract 63 experimental data on drug-
dose combinations, including placebo outcomes (34 when limited
to 12 weeks studies with 12 placebo studies and 47 when
limited to 26 weeks studies). When grouping these data together
using weighted averages, we end up with 22 diﬀerent drug-
dose combinations when trial duration was limited to 12 weeks.
For the change in OFF time, 41 drug-dose combinations were
identiﬁed (28 for 12 weeks with 12 placebo eﬀects, 40 for up
to 39 weeks). Smaller numbers of drug-dose combinations were
found for change in UPDRS II (39), change in UPDRS Total (29)
and change in ON time (21).
Adjusting the target engagement levels within a biological
range resulted in a correlation of R2 = 0.87 for the 22 drug-
dose combinations in the 12-weeks studies between QSP model
outcomes and clinically observed changes from baseline after
correction for the placebo eﬀect (Figure 5A). Using these same
parameters, we arrived at a correlation of R2 = 0.39 for the
16 placebo-normalized drug-dose combinations between the
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FIGURE 4 | (A) Dose-dependent decrease of subthalamic nucleus b/g (STN b/g) with various DA agonists. The simulations suggest that different agonists have
different outcomes dependent upon their affinity for pre- and post-synaptic D2R with the most recently developed rotigotine and pramepixole having a good robust
effect over a range of target engagement levels (expressed as hypothetical D2R occupancies) and with minimal liability of dyskinesia at higher doses. (B) Effect of
NMDA antagonism (NR2B subunit specific) on subthalamic nucleus b/g ratio. Such an approach increases STN beta/gamma ratio (STN b/g) and worsens
Parkinsonian symptoms. The number following “L-DOPA” refers to the increase in DA release (normalized to the basal release in the PD condition). The effect is
somewhat mitigated by the presence of L-DOPA, with higher L-DOPA comedication levels attentuating the negative effect of NMDA antagonism. Similar effects are
observed with an NMDA subtype a-specific inhibitor. (C) Adenosine A2AR antagonism reduces subthalamic nucleus b/g and improves clinical outcome only in the
presence of L-DOPA. The number following “L-DOPA” refers to the increase in DA release (normalized to the basal release in the PD condition). There is no effect or a
tendency for increased subthalamic nucleus b/g (and worsened clinical outcome) in the absence of L-DOPA. (D) Effect of serotonin transport inhibition and increased
5-HT tone on the subthalamic nucleus b/g ratio as a function of increased 5-HT half-life. The number following “L-DOPA” refers to the increase in DA release
(normalized to the basal release in the PD condition). Increased 5-HT tone reduces subthalamic nucleus b/g and improves PD motor symptoms. The effect is already
present in the absence of L-DOPA and is mitigated by increasing doses of L-DOPA.
clinically reported changes in OFF time and the QSP model
outcomes (Figure 5B).
Placebo Effect
Historically, a large placebo eﬀect has been observed in clinical
trials in PD. Our database suggests a placebo eﬀect of −9.5 ± 4.5
points on the UPDRS Part III Motor score in an acute setting
(four datapoints) and a placebo eﬀect of −1.73 ± 1.23 points
for chronic situations (eight datapoints). We hypothesized that
this placebo eﬀect was due to a transient dopamine surge.
Evidence for this comes from an acute 11C-raclopride PET
tracer displacement study in healthy volunteers (Boileau et al.,
2007; 23% displacement) and a chronic PET displacement study
with the dopamine transporter selective tracer 11C-RTI32 in
Parkinson’s patients (11% displacement; Guttman et al., 2001).
We calculated the increase in dopamine release that would
correspond to the clinically observed displacement of both PET
tracers using the humanized dopamine receptor competition
model (Figure 6A). This corresponds to an increase of 120%
for the acute situation and 40% for the chronic situation. Using
the correlation function determined above, we determined an
estimated improvement of 8.7 points on the UPDRS Part III
(close to the observed 7.8 points) for the acute placebo eﬀect.
Conversely for the chronic situation the model estimated a
placebo improvement of 2.85 points which is 39% greater than
the observed eﬀect in clinical situations (2.05; Figure 6B).
DISCUSSION
This report presents a QSP implementation of humanized
cortico-striatal-thalamo-cortical loop that drives motor
behavior. The computer model is based on the neuro-
anatomical relationship between diﬀerent basal ganglia
regions (Bazhenov et al., 1998; Rubin and Terman, 2004),
i.e., the cortico-striata-thalamo-cortical loop, the nature of
the speciﬁc cell types, and the GPCRs and both ligand- and
voltage-gated ion channels that modulate their respective
ﬁring activity. We then implemented the neuropathology
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FIGURE 5 | (A) Correlation between clinically reported changes between baseline and end-of-treatment (at most 12 weeks) in UPDRS-III score (placebo-controlled)
and corresponding QSP model outcomes in calculated subthalamic nucleus b/g (STN b/g). For each data-point the baseline-end-of-treatment difference for the
placebo arm of that study was subtracted. In the absence of clear target engagement data, these were optimized within biological ranges with respect for the target
engagement of different doses of the same compound. The data suggest that a high correlation can be achieved. (B) Correlation between clinically reported
changes between baseline and end-of-treatment in OFF-time for 15 drug-dose combinations in short-term studies (12 weeks) and the corresponding QSP model
outcomes (subthalamic nucleus b/g ratio), using the optimized parameters for calibration between UPDRS Part III Motor scores and the QSP model. For each
data-point the baseline-end-of-treatment difference for the placebo arm of that study was subtracted. The relatively modest correlation (0.386) is also driven by the
weak correlation between changes in UPDRS-Part III scores and changes in OFF-time for those studies that reported both outcomes.
FIGURE 6 | (A) Effect of placebo conditions on dopamine increase derived from PET studies in human volunteers and patients with Parkinson’s disease, in particular
the impact on D1 and D2R activation for various levels of dopamine depletion corresponding to Parkinsonian pathology. (B) Effect of placebo-induced DA increases
from (A) on the estimated clinical placebo response derived from our calibrated beta/gamma ratio. Shown are the different clinical studies reporting acute effects of
placebo with an average of −7.8 points, where the QSP model predicted an effect of −8.7 points (red line). Similarly, for the chronic placebo case, the average
clinical outcome was −2.0, whereas the QSP model predicted an improvement of −2.85 points (red line).
and compensatory changes due to Parkinson’s pathology
and ﬁnally calibrated with clinical data of actual clinical
interventions and their impact on UPDRS Part III Motor
Score.
With regard to the choice of the model readout, there is
ample biological evidence from deep-brain recordings in PD
patients that the local ﬁeld potential power spectrum in the
STN, rather than ﬁring frequency in any other region, is directly
related to motor symptoms such as bradykinesia and rigidity
(Alonso-Frech et al., 2006; Sharott et al., 2014). Interestingly,
the low-gamma power spectrum (30–45 Hz) is associated with
clinical tremor (Beudel et al., 2015). Therefore we calculate the
ratio of beta-power over gamma power of the local ﬁeld potentials
in the STN as an in silico biomarker for motor symptoms. This
also underscores at the same time the richness of information
contained in local ﬁeld potential oscillations and the extreme
diﬃculty to predict what the impact of a certain intervention at
a speciﬁc target would be without any computational support.
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The model captures the observation that clinical symptoms
(i.e., substantial changes in the beta/gamma ratio) become
apparent after 70% of dopamine tone is lost. This is partly due
to the non-linear interaction at the level of activation of post-
synaptic D1 and D2R when presynaptic dopamine release is
reduced.
The results suggest that the platform can achieve a robust
correlation with historical clinical trials, including the therapeutic
interventions that did not show a clinical beneﬁt. Part of this
high correlation with the UPDRS Part III Motor symptoms
is driven by the fact that we could adjust target engagement
levels for the diﬀerent drugs for which no actual target exposure
data were available (see further below). Using the same target
engagement levels the correlation between model outcome and
OFF time was smaller, suggesting that these clinical scales report
on diﬀerent clinical phenotypes. Indeed in the small number of
studies (n= 19) where both data are available for the same patient
groups, the correlation between changes inUPDRS Part IIIMotor
symptoms and OFF time was only R2 = 0.417.
It has to be noted also the biological coupling parameters were
all adjusted using the correlation between model outcome in a
schizophrenia environment and the reported clinical data on the
fraction of patients that needed anticholinergic medication to
address their EPS side-eﬀects. No further adjustment was made
for the PD state, except for the parameters that deﬁned the
neuroplasticity changes at the level of MSN-GPi and GPe-STN.
A major issue is the lack of target engagement in the reported
clinical trials. This is mainly due to the absence of good
radiotracers that can report on D2 agonism. In a small clinical
study pramexipole was documented to reduce the binding of
FLB457, a speciﬁc D2 antagonist radiotracer by 10% at a dose
of 0.125 mg and 20% at the dose of 0.25 mg (Ishibashi et al.,
2011). In contrast, a study with a speciﬁc radiotracer SCH442416
revealed that A2A antagonists can displace up to 90% (Brooks
et al., 2010), corresponding to an increase of D2R coupling to
A-type K+ channel of 65%. Where available, we used this target
engagement information together with the assumption of linear
pharmacokinetics for diﬀerent doses of the same drug. This
allows one to achieve a substantial correlation between historical
clinical reported studies and computer model outcomes for the
same drug-dose combinations.
The observations with serotonin transport inhibitors suggest
a substantial beneﬁcial eﬀect on STN b/g and therefore on
clinical symptoms improvement. However, higher doses of
SERT inhibitors are associated with severe side-eﬀects including
cognitive worsening (Porsteinsson et al., 2014), which can be an
issue, especially in elderly PD patients. This limits the usefulness
of this therapeutic intervention.
Limitations of the model include the level of resolution in
the diﬀerent basal ganglia subregions. Due to computational
constraints we only have a ﬁnite number of neurons in each basal
ganglia subregion, ranging from 4 to 16. This does not allow us
to more ﬁnely distinguish between diﬀerent subregions of each
basal ganglia region.
We do not model explicitly the impact of serotonergic
synapse derived dopamine with L-DOPA as proposed in earlier
computational models (Best et al., 2010; Reed et al., 2012);
for L-DOPA treatment we calibrated the response in terms of
increase in free DA levels, irrespective of the origin of DA release.
We acknowledge that this can be modulated by interventions
that change 5-HT tone such as SERT inhibitors or 5-HT1A/B
modulators. However, in vivo rat microdialysis studies suggest
that this eﬀect might be limited (Paolone et al., 2015).
While the computer model incorporates diﬀerent
neurotransmitter systems, such as dopamine, serotonin,
acetylcholine, adrenerge, glutamate and GABA, it falls short
on other systems that have been documented to be involved
in basal ganglia physiology and PD pathology, such as the
endocannabinoid system, reviewed in More and Choi (2015).
For instance, aﬀecting this systems with a phytocannabinoid
(9)-THCV that stimulates CB2 and blocks CB1 receptors
provide symptomatic relief and neuroprotection in animal
models (García et al., 2011). The cannabinoid agonist WIN
55212-2 has been studied extensively in preclinical animal
models of PD (Price et al., 2007; Morgese et al., 2009). However,
clinical trials to date have not shown an robust and reproducible
eﬀect (Kluger et al., 2015), illustrating the complex pharmacology
of this neurotransmitter system.
The endocannabinoid system aﬀect dopaminergic signaling
possibly through a heterodimerization between CB1 and D2
(Marcellino et al., 2008) and modulates glutamate (Grundy et al.,
2001) and GABA levels (Brotchie, 2003), in addition to direct
eﬀects on MSN excitability (Aceves et al., 2011). This might lead
to very complex non-linear interactions that could in principle
be simulated in the QSP model with regard to the eﬀect on ﬁeld
potential oscillations, especially in the presence of comedications
such as L-DOPA or DA agonists. A detailed simulation of the
clinical trials with these compounds could also shed some light
on why some trials are successful and others fail.
The biology of the human basal ganglia is very complex and
this computer model certainly does not include all biological
processes that possibly might play a role. Detailed modeling
of all the biological processes of complex circuits is still years
away, but reconstruction and simulation of a small neocortical
circuit has been reported as a ﬁrst small step (Markram et al.,
2015). However, we would argue that the level of granularity and
detail in our computer model although incomplete has value for
therapeutic applications in the pharmaceutical industry. Animal
models might be more complete, but lack translationability to the
human clinical situation. In that regard, QSPhas a place alongside
traditional preclinical animal models in Drug Discovery and
Development as it is an independent and more humanized
and clinically calibrated, albeit simpler tool. We also posit that
such computer modeling platforms will become better and more
predictive as they learn from failed clinical trials and ultimately
become a actionable Knowledge Repository platform, not unlike
the concept of Computer-Aided Design in engineering industries.
Obviously the real validation of this approach for PD will be in
the blinded prospective prediction of a clinical trial outcome for
new untested drug, similar to the case for the QSP prediction of
a novel Alzheimer drug (Nicholas et al., 2013) or new untested
drugs for schizophrenia (Geerts et al., 2012; Liu et al., 2014).
This simulation platform in its current form also does
not address the issue of neurotoxicity and is only intended
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to study symptomatic eﬀects. In order to minimize possible
neuroprotective eﬀects on speciﬁc interventions we limited the
duration of clinical trials for the calibration to 12 weeks. These
and other biological processes like the endocannabinoid systems
can in principle be added later into a more comprehensive
model.
In summary, this report documents a QSP model of a closed
cortico-striatal-thalamocortical loop of the motor striatum that
is fully calibrated using human clinical data on therapeutic
interventions in PD. The platform could be used to support the
development of new symptomatic drugs or to evaluate the impact
of various comedications in clinical practice. In principle, this
model could also be expanded to simulate the complex emergent
properties of other cortico-basal ganglia loops such as the meso-
limbic or associative loops and therefore could address other
important questions, such as psychiatric symptoms like obsessive
behavior, agitation or cognitive aspects.
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